These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33305459)

  • 1. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
    Di Gregorio M; Torri Clerici VLA; Fenu G; Gaetani L; Gallo A; Cavalla P; Ragonese P; Annovazzi P; Gajofatto A; Prosperini L; Landi D; Nicoletti CG; Di Carmine C; Totaro R; Nociti V; De Fino C; Ferraro D; Tomassini V; Tortorella C; Righini I; Amato MP; Manni A; Paolicelli D; Iaffaldano P; Lanzillo R; Moccia M; Buttari F; Fantozzi R; Cerqua R; Zagaglia S; Farina D; De Luca G; Buscarinu MC; Pinardi F; Cocco E; Gasperini C; Solaro CM; Di Filippo M
    Eur J Neurol; 2021 Apr; 28(4):1299-1307. PubMed ID: 33305459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
    Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
    Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
    Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
    Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
    Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
    Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
    Jain RS; Khan I; Kandelwal K; Desai T
    Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
    Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
    Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
    Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
    Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations.
    Li X; Miao X; Wang Y; Sun J; Gao H; Han J; Li Y; Wang Q; Sun C; Liu J
    Front Immunol; 2022; 13():1052678. PubMed ID: 36532021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology.
    Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF
    Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
    Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
    J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
    Jeong IH; Kim SH; Hyun JW; Joung A; Cho HJ; Kim HJ
    J Neurol Sci; 2015 Nov; 358(1-2):118-24. PubMed ID: 26333950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.
    Fereidan-Esfahani M; Decker PA; Eckel Passow JE; Lucchinetti CF; Flanagan EP; Tobin WO
    Eur J Neurol; 2022 Mar; 29(3):782-789. PubMed ID: 34773343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
    Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
    AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study.
    Kolčava J; Kočica J; Hulová M; Dušek L; Horáková M; Keřkovský M; Stulík J; Dostál M; Kuhn M; Vlčková E; Bednařík J; Benešová Y
    Mult Scler Relat Disord; 2020 Sep; 44():102262. PubMed ID: 32570179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
    Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
    J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
    Tintore M; Rovira À; Río J; Otero-Romero S; Arrambide G; Tur C; Comabella M; Nos C; Arévalo MJ; Negrotto L; Galán I; Vidal-Jordana A; Castilló J; Palavra F; Simon E; Mitjana R; Auger C; Sastre-Garriga J; Montalban X
    Brain; 2015 Jul; 138(Pt 7):1863-74. PubMed ID: 25902415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
    Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
    Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
    Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
    Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
    Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
    Front Immunol; 2022; 13():986473. PubMed ID: 36059526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.